Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: Efficacy, safety and patient selection

Giovanni Abbruzzese, Paolo Barone, Ubaldo Bonuccelli, Leonardo Lopiano, Angelo Antonini

Research output: Contribution to journalArticlepeer-review

Abstract

Long-term oral therapy with levodopa is associated with the development of motor fluctuations and dyskinesia in a large percentage of patients with Parkinson's disease (PD). Motor complications are associated with a number of non-motor symptoms and have a negative impact on disability and quality of life. There are three therapeutic options available for the management of patients at this advanced stage: high frequency deep brain stimulation, continuous subcutaneous infusion of apomorphine, and continuous intestinal infusion of levodopa/carbidopa. On the basis of published data and in consideration of the risk-benefit profile of current therapeutic strategies, we here propose an algorithm to help clinicians select the most suitable treatment option for patients with advanced PD.

Original languageEnglish
Pages (from-to)147-154
Number of pages8
JournalFunctional Neurology
Volume27
Issue number3
Publication statusPublished - Jul 2012

Keywords

  • Continuous dopaminergic stimulation
  • Deep brain stimulation
  • Levodopa/carbidopa intestinal gel infusion
  • Parkinson's disease
  • Patient selection

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: Efficacy, safety and patient selection'. Together they form a unique fingerprint.

Cite this